Association between nerve growth factor gene polymorphism and executive dysfunction in Japanese patients with early-stage Alzheimer's disease and amnestic mild cognitive impairment

Dementia and Geriatric Cognitive Disorders

Volumn 32, Issue 6, 2012, Pages 379-386

  Nagata, Tomoyuki ^a,b   Shinagawa, Shunichiro ^a   Nukariya, Kazutaka ^b   Nakayama, Ritsuko ^a   Nakayama, Kazuhiko ^a   Yamada, Hisashi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Executive function; Frontal Assessment Battery; Nerve growth factor; Neurotrophin; Single nucleotide polymorphisms

Indexed keywords

NERVE GROWTH FACTOR;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; ATTENTION; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXECUTIVE FUNCTION; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MILD COGNITIVE IMPAIRMENT; NERVE GROWTH FACTOR; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84856489356     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000335355     Document Type: Article

References (58)

1. Perry RJ, Watson P, Hodge JR: The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia 2000; 38: 252-271.
2. Baudic S, Barba GD, Thibaudet MC, Smagghe A, Remy P, Traykov L: Executive function deficit in early Alzheimer's disease and their relations with episodic memory Arch Clin Neuropsychol 2006; 21: 15-21
3. Perry RJ, Hodges JR: Attention and executive deficits in Alzheimer's disease. A critical review. Brain 1999; 122: 383-404.
4. Buckner RL: Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004; 44: 195-208.
5. Bartus RT: On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529.
6. Perry EK, Curtis M, Dick DJ, et al: Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413-421.
7. Schaeffer EL, Forlenza OV, Gattaz WF: Phospholipase A 2 activation as a therapeutic approach for cognitive enhancement in earlystage Alzheimer disease. Psychopharmacology 2009; 202: 37-51.
8. Tabert MH, Manly JJ, Liu X, et al: Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006; 63: 916-924.
9. Maisonpierre PC, Belluscio L, Friedman B, et al: NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990; 5: 501-509.
10. Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
11. Conner JM, Franks KM, Titterness AK, et al: NGF is essential for hippocampal plasticity and learning. J Neurosci 2009; 29: 10883-10889.
12. Schindowski K, Belarbi K, Buee L: Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008;(suppl 1):43-56.
13. Whittemore SR, Ebendal T, Lärkfors L, et al: Development and regional expression of-nerve growth factor messenger RNA and protein in the rat central nervous system. Proc Natl Acad Sci USA 1986; 83: 817-821.
14. Svendsen CN, Cooper JD, Sofroniew MV: Trophic factor effects on septal cholinergic neurons. Ann NY Acad Sci 1991; 640: 91-94.
15. da Penha Berzaghi M, Cooper J, Castrén E, et al: Cholinergic regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) but not neurotrophin-3 (NT-3) mRNA levels in the developing rat hippocampus. J Neurosci 1993; 13: 3818-3826.
16. Capsoni S, Tiveron C, Vignone D, Amato G, Cattaneo A: Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficitinduced neurodegeneration. Proc Natl Acad Sci USA 2010; 107: 12299-12304.
17. Calissano P, Matrone C, Amadoro G: Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Dev Neurobiol 2010; 70: 372-383.
18. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF: Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 2010; 40: 230-235.
19. Cuello AC, Bruno MA: The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res 2007; 32: 1041-1045.
20. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A: Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000; 97: 6826-6831.
21. Fahnestock M, Michalski B, Xu B, Coughlin MD: The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001; 18: 210-220.
22. Peng S, Wuu J, Mufson EJ, Fahnestock M: Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 2004; 63: 641-619.
23. Hock C, Heese K, Hulette C, Rosenberg C, Otten U: Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-851.
24. Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervós-Navarro J: NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci 1998; 16: 787-794.
25. Stokin GB, Lillo C, Falzone TL, et al: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005; 307: 1282-1288.
26. Dai J, Buijs RM, Kamphorst W, Swaab DF: Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 2002; 948: 138-144.
27. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J: Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 2008; 41: 196-199.
28. Akkad DA, Kruse N, Arning L, Gold R, Epplen JT: Genomic NGFB variation and multiple sclerosis in a case control study. BMC Med Genet 2008; 9: 107.
29. Lee R, Kermani P, Teng KK, Hempstead BL: Regulation of cell survival by secreted proneurotrophins. Science 2000; 294: 1945-1958.
30. Syed Z, Dudbridge F, Kent L: An investigation of the neurotrophic factor genes GDNF, NGF, and NT3 in susceptibility to ADHD. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:375-378.
31. Miyajima F, Ollier W, Mayes A, et al: Brainderived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 2008; 7: 411-417.
32. Nagata T, Shinagawa S, Nukariya K, et al: Association between brain-derived neurotrophic factor (BDNF) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease. Psychogeriatrics 2011; 11: 141-149.
33. Desai P, Nebes R, DeKosky ST, Kamboh MI: Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression. Neurosci Lett 2005; 379: 229-234.
34. Akatsu H, Yamagata HD, Kawamata J, et al: Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord 2006; 22: 216-222.
35. Combarros O, Infante J, Llorca J, Berciano J: Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 18: 55-58.
36. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-1626.
37. Takagi R, Kajimoto Y, Kamiyoshi S, Miwa H, Kondo T: The frontal assessment battery at bed side (FAB) in patients with Parkinson's disease (in Japanese). No To Shinkei. 2002; 54: 897-902.
38. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
39. Petersen RC, Doody R, Kurz A, et al: Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
40. Erkinjuntti T: Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl 2003; 63: 91-109.
41. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
42. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
43. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(suppl):9-15.
44. Zanetti M, Ballabio C, Abbate C, Cutaia C, Vergani C, Bergamaschini L: Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study. J Am Geriatr Soc 2006; 54: 580-586.
45. Huang R, Poduslo SE: CYP19 haplotypes increase risk for Alzheimer's disease. J Med Genet 2006; 43:e42.
46. Guillem K, Bloem B, Poorthuis RB, et al: Nicotinic acetylcholine receptor-2 subunits in the medial prefrontal cortex control attention. Science 2011; 333: 888-891.
47. Dalley JW, Theobald DE, Bouger P, Chudasama Y, Cardinal RN, Robbins TW: Cortical cholinergic function and deficits in visual attentional performance in rats following 192 IgG-saporin-induced lesions of the medial prefrontal cortex. Cereb Cortex 2004; 14: 922-932.
48. Tuszynski MH, Thal L, Pay M, et al: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
49. Tuszynski MH: Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 179-189.
50. Amieva H, Phillips LH, Della Sala S, Henry JD: Inhibitory functioning in Alzheimer's disease. Brain 2004; 127: 949-964.
51. Collette F, Amieva H, Adam S, et al: Comparison of inhibitory functioning in mild Alzheimer's disease and frontotemporal dementia. Cortex 2007; 43: 866-874.
52. Nagata T, Shinagawa S, Ochiai Y, et al: Association between executive dysfunction and hippocampal volume in Alzheimer's disease. Int Psychogeriatr 2010, Epub ahead of print.
53. Amieva H, Lafont S, Rouch-Leroyer I et al: Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test. Arch Clin Neuropsychol 2004; 19: 791-803.
54. Houeland G, Romani A, Marchetti C, et al: Transgenic mice with chronic NGF deprivation and Alzheimer's disease-like pathology display hippocampal region-specific impairments in short-and long-term plasticities. J Neurosci 2010; 30: 13089-13094.
55. Delbeuck X, Van der Linden M, Collette F: Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev 2003; 13: 79-92.
56. Shadrina M, Kolomin T, Agapova T, et al: Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci 2010; 41: 30-35.
57. Wilson BA, Cockburn J, Baddeley A: The Rivermead Behavioural Memory Test. Fareham, Themus Valley Test Co, 1985, pp 34-36.
58. Wechsler D: The Wechsler Memory Scale. San Antonio, Psychological Corporation, 1990.